aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-12-08 18:02Core Viewpoint - The article discusses a securities class action lawsuit against aTyr Pharma, Inc. following an 83% stock collapse due to the failure of its drug trial, highlighting allegations of misleading information provided by the company regarding the efficacy of its drug, Efzofitimod [1][2]. Legal Allegations - The lawsuit claims that aTyr and its executives misrepresented the efficacy of Efzofitimod, leading to inflated stock prices and subsequent losses for investors [2][3]. - The core issue revolves around whether the company accurately represented its clinical trial data and design, particularly regarding the drug's ability to allow patients to taper off steroid usage [3][4]. Trial Performance and Impact - The primary endpoint of the Phase 3 EFZO-FIT study was not met, specifically regarding the change in mean daily oral corticosteroid dose [5]. - Allegations include the concealment of adverse facts about the drug's performance, which could mislead investors about its true efficacy [5]. - Following the announcement of the trial results, aTyr's stock plummeted from $6.03 to $1.02, representing an 83.2% loss on September 15, 2025 [5]. Investor Guidance - Hagens Berman is advising investors who purchased aTyr shares between November 7, 2024, and September 12, 2025, and suffered losses to submit their claims by the December 8, 2025, deadline [6]. - The firm has a history of securing over $2.9 billion in settlements for investors in similar cases, emphasizing the importance of accurate disclosures in clinical trials [6][7].